Metastatic Prostate Cancer
Recently Published Documents


TOTAL DOCUMENTS

3366
(FIVE YEARS 1638)

H-INDEX

97
(FIVE YEARS 39)

Author(s):  
Elahe Mahmoudi ◽  
Elahe Pirayesh ◽  
Mohammad Reza Deevband ◽  
Mahasti Amoui ◽  
Mehrdad Ghorbani Rad ◽  
...  

The Prostate ◽  
2021 ◽  
Author(s):  
Benedikt Hoeh ◽  
Christoph Würnschimmel ◽  
Rocco S. Flammia ◽  
Benedikt Horlemann ◽  
Gabriele Sorce ◽  
...  

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100261
Author(s):  
A.A. Kulkarni ◽  
N. Rubin ◽  
A. Tholkes ◽  
S. Shah ◽  
C.J. Ryan ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4607
Author(s):  
Dora Londra ◽  
Sophia Mastoraki ◽  
Evangelos Bournakis ◽  
Martha Zavridou ◽  
Anastasios Thanos ◽  
...  

Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of circulating tumor cells (CTCs) and plasma-circulating tumor DNA (ctDNA). USP44 is a critical gene which plays an important role in cell proliferation; however, its accurate role in other cellular networks is under research. USP44 promoter methylation has been so far reported in colorectal neoplasia and metastatic breast cancer. In this study, we examined for the first time USP44 promoter methylation in plasma cell-free DNA (cfDNA) of patients with prostate cancer (early stage n = 32, metastatic n = 39) and 10 healthy donors (HD). USP44 promoter methylation was detected in plasma cell-free DNA by a newly developed highly specific and sensitive real-time MSP method. Our findings indicate that USP44 promoter is methylated in plasma cell-free DNA of metastatic prostate cancer patients and that detection of USP44 promoter methylation is significantly associated with overall survival (OS) (p = 0.008). We report for the first time that detection of USP44 promoter methylation in plasma cell free DNA provides significant prognostic information in metastatic prostate cancer.


2021 ◽  
Vol 11 ◽  
Author(s):  
Luc Ollivier ◽  
Maureen Labbé ◽  
Delphine Fradin ◽  
Vincent Potiron ◽  
Stéphane Supiot

Prostate cancer is the most frequently diagnosed cancer in men and a leading cause of cancer-related death. In recent decades, the development of immunotherapies has resulted in great promise to cure metastatic disease. However, prostate cancer has failed to show any significant response, presumably due to its immunosuppressive microenvironment. There is therefore growing interest in combining immunotherapy with other therapies able to relieve the immunosuppressive microenvironment. Radiation therapy remains the mainstay treatment for prostate cancer patients, is known to exhibit immunomodulatory effects, depending on the dose, and is a potent inducer of immunogenic tumor cell death. Optimal doses of radiotherapy are thus expected to unleash the full potential of immunotherapy, improving primary target destruction with further hope of inducing immune-cell-mediated elimination of metastases at distance from the irradiated site. In this review, we summarize the current knowledge on both the tumor immune microenvironment in prostate cancer and the effects of radiotherapy on it, as well as on the use of immunotherapy. In addition, we discuss the utility to combine immunotherapy and radiotherapy to treat oligometastatic metastatic prostate cancer.


2021 ◽  
Author(s):  
Mingxiong Sheng ◽  
Shanming Guo ◽  
Chunxiao Liu

Abstract Background: The study aimed to assess the value of circulating tumor cells (CTCs) as a prognostic and treatment response marker in patients undergoing androgen deprivation therapy (ADT) plus cryosurgery vs. ADT alone for metastatic prostate cancer (mPCA).Methods: This retrospective analysis included 43 patients with mPCA: 23 receiving ADT alone (control) and 20 receiving additional cryosurgery (cryosurgery group).CTCs and progression-free survival(PFS) were compared between the two groups. Cox proportional hazards regression was conducted to identify variables associated with PFS.Results: Median PFS was 35 months (IQR: 33-37) in the cryosurgery group vs. 30 months (IQR: 27-32) in the control (p<0.001). CTCs count was significantly lower in the cryosurgery group at both 3 months (z=2.170, p=0.030) and 12 months (z=2.481; p=0.013). In comparison to the baseline, the number of CTCs at both 3 and 12 months was lower in the cryosurgery group (p=0.004 and p<0.001, respectively), but not in the ADT alone group. In multivariate Cox regression, shorter PFS was associated with baseline PSA ≧100 ng/ml (HR 6.584, 95%CI: 5.309-8.166), biopsy Gleason score≧8 (HR 2.064, 95%CI: 1.608-2.650), clinic T stage>T2b (HR 5.021, 95%CI: 3.925-6.421), number of bone metastases>3 (HR 3.421, 95%CI: 2.786-4.202), positive CTCs at 3 months post-treatment (HR 6.833, 95%CI: 5.176-9.022), positive CTCs 1 year post-treatment (HR 6.051, 95%CI: 4.347-8.424). Prostate cryosurgery was associated with longer PFS(HR 0.062, 95%CI: 0.048-.080). Conclusions: CTC was a prognostic and treatment response marker for mPCA. ADT plus cryosurgery could reduce CTCs and prolong PFS vs. ADT alone in mPCA patients with low metastatic volume.


2021 ◽  
pp. OP.21.00206
Author(s):  
Nicolas Sayegh ◽  
Umang Swami ◽  
Neeraj Agarwal

Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. Several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide) in the metastatic castration-sensitive state. Relugolix has been recently approved as the first oral gonadotropin-releasing hormone receptor antagonist agent with a superior cardiovascular side-effect profile, and serum testosterone suppression compared with a gonadotropin-releasing hormone agonist, leuprolide. Poly-ADP ribose polymerase inhibitors (olaparib and rucaparib) have demonstrated significant clinical benefit for patients harboring deleterious mutations in genes belonging to the homologous recombination repair pathway and have received Food and Drug Administration approval. Recently, lutetium-177-prostate-specific membrane antigen-617 with standard of care treatment has shown to improve overall survival in men with advanced-stage prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. These recent approvals, successes, and the ongoing investigation of multiple novel agents are expected to continue to dramatically improve survival outcomes of men with metastatic prostate cancer in the coming years.


2021 ◽  
pp. jnumed.121.262371
Author(s):  
Aloÿse Fourquet ◽  
Adrian Rosenberg ◽  
Esther Mena ◽  
Joanna J. Shih ◽  
Baris Turkbey ◽  
...  

2021 ◽  
Vol 32 ◽  
pp. S677
Author(s):  
A.K. Jayaram ◽  
A. Reid ◽  
G. Wheeler ◽  
C. Alifrangis ◽  
J. O'Dwyer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document